Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Hosted on MSN16h
NTDs: Oyo Reiterates Commitment To Disease Elimination, Says Untreated Cases Can Lead To Loss Of Sight, Death
IBADAN – Oyo State Government has reiterated its commitment to eradicate the Neglected Tropical Diseases (NTDs) in the state, while warning that untreated cases could lead to loss of sight and death.
yr.no10h
Praia d'El Rey Golf & Beach Resort
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...